Creo Medical Group PLC LTIP Awards and Issue of Equity (3952D)
19 February 2020 - 6:00PM
UK Regulatory
TIDMCREO
RNS Number : 3952D
Creo Medical Group PLC
19 February 2020
Creo Medical Group plc
("Creo" the "Company" or the "Group")
LTIP Awards and Issue of Equity
Creo Medical Group plc (AIM: CREO), the medical device company
focused on the emerging field of surgical endoscopy, announces that
it is giving effect to the disclosure made in the Circular dated 4
December 2019, and has as of 18 February 2020, granted the
following Directors ("Participants") an interest over 370,000
ordinary shares ("LTIP Shares") of 0.1 pence each in the capital of
the Company ("Ordinary Shares"), representing approximately 0.2% of
the enlarged issued share capital of the Company, pursuant to the
Company's newly established Long Term Incentive Plan ("LTIP").
Director Position LTIP Shares
----------------- ------------------ ------------
Chief Executive
Craig Gulliford Officer 140,000
Chief Technology
Chris Hancock Officer 115,000
Chief Finance
Richard Rees Officer 115,000
The Company has made an application for 7,000,000 new Ordinary
Shares to be admitted to trading on AIM. These new Ordinary Shares
will be held by the Company's Employee Benefit Trust ("EBT") and
will be used to satisfy exercises of shares currently under option,
as well as for future LTIP awards. The voting rights on these new
Ordinary Shares will be exercisable by the trustee of the EBT
("Trustee") at its sole discretion.
The Participant and the Trustee jointly own the beneficial
interest of the LTIP Shares. The Participant is entitled to any
value above the Hurdle Price of GBP2.50 per share and the Trustee
entitled to all value below the Hurdle Price. The Participant has
also been granted an option to acquire the Trustee's beneficial
interest in the LTIP shares, which vests three years after the
acquisition date (subject to remaining in eligible employment) and
the exercise of which is subject to a three-month holding period
once vested.
Application will be made for 7,000,000 new Ordinary Shares to be
admitted to trading on AIM. It is expected that admission will take
place on 21 February 2020. Following the allotment and issue, the
Company's issued share capital consists of 157,484,021 Ordinary
Shares. The Company does not hold any shares in Treasury, as such
the total number of shares in issue with voting rights is
157,484,021.
The above figure of 157,484,021 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Creo Medical Group plc investors.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Cameron MacRitchie
(NOMAD)
Michael Johnson / Russell
Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7515
909 238
The following notifications are intended to satisfy the
Company's obligations under Article 19(3) of EU Regulation No
596/2014 (the Market Abuse Regulation).
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name 1. Craig Gulliford
2. Chris Hancock
3. Richard Rees
----------------------------- ---------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status 1. Chief Executive Officer
2. Chief Technology Officer
3. Chief Finance Officer
----------------------------- ---------------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Creo Medical Group plc
----------------------------- ---------------------------------------------
b) LEI 213800H188ZDCWWXFA21
----------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.001 each
financial instrument,
type of instrument
Identification code GB00BZ1BLL44
b) Nature of the transaction Allocation of Ordinary Shares under
the Creo Medical Group plc LTIP
2020
----------------------------- ---------------------------------------------
c) Price(s) and volume(s)
--------------- ------------
Price(s) pence Volume(s)
--------------- ------------
1. nil 1. 140,000
2. nil 2. 115,000
3. nil 3. 115,000
--------------- ------------
d) Aggregated information
- Aggregated volume N/A - single transaction
- Price
e) Date of the transaction 18 February 2020
----------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- ---------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAXAPFSLEEFA
(END) Dow Jones Newswires
February 19, 2020 02:00 ET (07:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024